The system
How the system worksThe DirectoryDispatchThe LedgerAI modelsAI agentsYour installationThe appThe research libraryWhat changes for your businessUse it from your softwareEverything it can do
Messaging
iMessageWhatsApp
Ads and leads
AdsCreativeLeads
Devices
Devices
Industries
RealtorsRestaurantsHome services
Explore
How it worksPermissions and limitsCompareSet upQuestionsText me

tirzepatide glp1 agonists

Evidence is being populated by Grok web

Overview

Evidence is being populated by Grok web search.

References (9)
  1. Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration“A dose-dependent tirzepatide was superior to placebo and GLP-1 RAs in weight reduction. However, the lean mass reduction and tolerability require further investigation.”
  2. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial“We evaluated the efficacy and safety of continuing tirzepatide at the maximum tolerated dose (MTD) or lowering the dose to 5 mg compared with placebo.”
  3. Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes“This mechanistic study will define mechanisms by which GLP1-GIP co-agonism may uniquely provide clinical benefits in T1D during the fasting and fed states.”
  4. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity“Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight.”
  5. Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Clinical Trial“Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.”
  6. Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis“These findings suggest that tirzepatide provides cardiovascular benefit at least comparable to established GLP-1RAs, supporting its emerging role in cardiovascular risk reduction in T2D.”
  7. Causes and consequences of discontinuation of GLP1RAs and tirzepatide“In this Review, we discuss common reasons for GLP1R agonist and tirzepatide discontinuation and examine available evidence related to potential cardiometabolic ...”
  8. Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists“Among patients with T2D taking a GLP-1 RA, tirzepatide was associated with lower risks of retinal complications, need for vision-saving ...”
  9. Weight Loss With GLP-1 Agonists in Nondiabetic Adults“Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes.”